PMC9573961_01
Hematological parameters prior to and following the start of ruxolitinib treatment. The dotted line on the graph indicates the day on which ruxolitinib treatment was started. (A) Absolute neutrophil count. (B) Hemoglobin level. (C) Absolute platelet count. (D) Triglyceride level. (E) Fibrinogen level. NEUT: neutrophil.
fimmu-13-1012643-g001.jpg
PMC9573961_02_fimmu-13-1012643-g001.jpg
f1
He was found to have neutropenia (neutrophil count: 0.84 x 109/L), anemia (hemoglobin level: 78 g/L), and severe thrombocytopenia (platelet count: 7 x 109/L) ( Figure 1A-C ). His triglyceride, fibrinogen, ferritin and D-dimer levels were 3.63 mmol/L, 0.91 g/L,6070 ng/mL, and 32960 microg/L, respectively ( Figures 1D, E  and  Figure 2A ). His neutrophil and platelet counts improved to 2.34 x 109/L and 27 x 109/L ( Figure 1A, C ), respectively, and CRP level decreased to 34.3 mg/ml. After therapy for 14 days, his hemoglobin level and platelet count increased to 108 g/l and 66 x 109/L, respectively, and neutrophil count, kidney function, and triglyceride level normalized ( Figure 1 ).
Ferritin and cytokine level before and after the initiation of ruxolitinib treatment. The dotted line on the graph indicates the day on which ruxolitinib treatment was started. (A) Ferritin level. (B) IL-6 level. (C) IL-10 level. (D) IFN-gamma level. IL: interleukin; IFN: interferon.
fimmu-13-1012643-g002.jpg
PMC9573961_02_fimmu-13-1012643-g002.jpg
f2
The levels of IL-6, IL-10, and IFN-gamma were markedly high ( Figure 2B-D ). His triglyceride, fibrinogen, ferritin and D-dimer levels were 3.63 mmol/L, 0.91 g/L,6070 ng/mL, and 32960 microg/L, respectively ( Figures 1D, E  and  Figure 2A ). Figure 2 ). Furthermore, ultrasound showed that hepatosplenomegaly resolved (thickness of 3.5cm).
PMC9573961_02
Hematological parameters prior to and following the start of ruxolitinib treatment. The dotted line on the graph indicates the day on which ruxolitinib treatment was started. (A) Absolute neutrophil count. (B) Hemoglobin level. (C) Absolute platelet count. (D) Triglyceride level. (E) Fibrinogen level. NEUT: neutrophil.
fimmu-13-1012643-g001.jpg
PMC9573961_02_fimmu-13-1012643-g001.jpg
f1
He was found to have neutropenia (neutrophil count: 0.84 x 109/L), anemia (hemoglobin level: 78 g/L), and severe thrombocytopenia (platelet count: 7 x 109/L) ( Figure 1A-C ). His triglyceride, fibrinogen, ferritin and D-dimer levels were 3.63 mmol/L, 0.91 g/L,6070 ng/mL, and 32960 microg/L, respectively ( Figures 1D, E  and  Figure 2A ). His neutrophil and platelet counts improved to 2.34 x 109/L and 27 x 109/L ( Figure 1A, C ), respectively, and CRP level decreased to 34.3 mg/ml. After therapy for 14 days, his hemoglobin level and platelet count increased to 108 g/l and 66 x 109/L, respectively, and neutrophil count, kidney function, and triglyceride level normalized ( Figure 1 ).
Ferritin and cytokine level before and after the initiation of ruxolitinib treatment. The dotted line on the graph indicates the day on which ruxolitinib treatment was started. (A) Ferritin level. (B) IL-6 level. (C) IL-10 level. (D) IFN-gamma level. IL: interleukin; IFN: interferon.
fimmu-13-1012643-g002.jpg
PMC9573961_02_fimmu-13-1012643-g002.jpg
f2
The levels of IL-6, IL-10, and IFN-gamma were markedly high ( Figure 2B-D ). His triglyceride, fibrinogen, ferritin and D-dimer levels were 3.63 mmol/L, 0.91 g/L,6070 ng/mL, and 32960 microg/L, respectively ( Figures 1D, E  and  Figure 2A ). Figure 2 ). Furthermore, ultrasound showed that hepatosplenomegaly resolved (thickness of 3.5cm).